For Pharma & Biotech
Accelerate drug development with QuantClinica's AI-enhanced EDC platform. Designed for the complexity, scale, and regulatory rigor of pharmaceutical clinical trials — from Phase I through Phase IV.
Pharmaceutical companies face increasing pressure to bring drugs to market faster while maintaining the highest standards of data integrity, patient safety, and regulatory compliance. Traditional data management approaches struggle with the scale and complexity of modern global trials.
QuantClinica EDC addresses these challenges with a unified platform that streamlines data capture, enhances quality through AI-driven insights, and ensures compliance across all major regulatory frameworks.
From Phase I through Phase IV, manage every stage of clinical development with consistent data standards and processes.
Predictive analytics and anomaly detection help identify data quality issues early, reducing query volume and study delays.
Multi-country, multi-language, multi-regulatory support. One platform for global drug development programs.
Built-in compliance with FDA, EMA, 21 CFR Part 11, ICH GCP, HIPAA, GDPR, and CDISC standards.
Encryption at rest and in transit, role-based access, audit trails, and IP-safe architecture for proprietary drug data.
Connect with LIMS, EHR/EMR, CTMS, eTMF, and analytics platforms through standard APIs and data exchange formats.
Clinical data management from Phase I through Phase IV requires precision, speed, and ironclad compliance. QuantClinica's EDC platform delivers across the metrics that matter most to pharmaceutical organisations.
Studies reach database lock up to 40% faster with AI-driven query reduction and automated data cleaning workflows.
Anomaly detection and edit checks catch discrepancies before they become formal queries, saving weeks of back-and-forth.
Deploy studies across 50+ countries with local-language support, regional compliance templates, and multi-site coordination.
Complete 21 CFR Part 11 compliant audit trails with tamper-evident logging, e-signatures, and full regulatory audit readiness.
Our team combines deep clinical research knowledge with modern software engineering. We understand the regulatory landscape because we've built for it.
India-based development and support deliver enterprise-grade EDC at competitive pricing — without compromising quality or compliance.
Dedicated support team available for study setup, configuration, training, and ongoing operational support.
QuantClinica EDC provides pharmaceutical organisations with a comprehensive toolkit purpose-built for the rigours of drug development. Every feature is designed to accelerate timelines while strengthening data integrity and regulatory compliance.
Configure study build, CRF design, visit schedules, and data validation rules without custom coding. Deploy new protocols in days, not months. Reuse templates across Phase I—IV to maintain consistency.
Safeguard proprietary drug formulations, biomarker data, and compound information with granular role-based access, data masking, and IP-secured architecture. Full separation between sponsor and investigator data domains.
Orchestrate multi-site, multi-country studies from a single dashboard. Manage site-level permissions, local language CRFs, time zone aware scheduling, and region-specific regulatory submissions simultaneously.
Export data in CDISC SDTM and ADaM formats ready for FDA and EMA submission. Generate audit-ready reports, eCTD-compatible outputs, and investigator brochure data packages on demand.
Live adverse event tracking, SAE reconciliation with safety databases, and automated MedDRA coding. Configurable alerts for safety signals and DSMB review triggers keep your patients safe.
Machine learning models trained on historical trial data detect anomalous entries, missing fields, and inconsistent patterns. Reduce query volume by up to 60% and accelerate database lock by 40%.
Secure portals for CROs, central labs, imaging vendors, and other partners. Controlled data access with audit trails ensures every party sees only what they need, when they need it.
Seamlessly migrate legacy trial data from any EDC system via standardised import pipelines. RESTful APIs, OData endpoints, and FHIR connectivity enable integration with your existing tech stack.
Pharmaceutical clinical trials operate under one of the most stringent regulatory environments in the world. QuantClinica EDC is architected from the ground up to meet and exceed the requirements of global health authorities. Our platform fully supports FDA 21 CFR Part 11 with electronic signatures, user authentication, audit trails, and record retention in accordance with the rule's validation requirements. Compliance with ICH GCP E6(R3) is embedded into every workflow — from informed consent tracking to source data verification and serious adverse event reporting. For sponsors conducting trials in Europe, the platform enforces EMA Clinical Trial Regulation (EU) No. 536/2014 requirements, including EudraCT and CTIS integration points. GDPR data protection principles are applied by design, with data minimisation, purpose limitation, and subject access request workflows built directly into the system. Beyond these core frameworks, QuantClinica supports HIPAA compliance for US-based studies, CDISC data standard conformance for regulatory submissions, and ISO 27001-aligned information security management. Our dedicated compliance team monitors regulatory updates continuously, ensuring that your studies remain audit-ready regardless of how the landscape evolves.
In Phase I trials, the focus is on safety, tolerability, and pharmacokinetics in a small cohort of healthy volunteers or patients. QuantClinica EDC enables rapid study setup with flexible CRF templates designed for intensive safety monitoring, dose-escalation tracking, and real-time adverse event capture. Automated alerts notify investigators of lab values outside predefined ranges, and integrated PK/PD parameter calculations support early go/no-go decisions.
Phase II trials expand the patient population to establish efficacy signals and optimal dosing. Our platform supports adaptive trial designs with dynamic CRF sections that appear based on prior responses, interim analysis data locks, and seamless transition between dose cohorts. Integrated patient-reported outcome instruments and biomarker data collection provide the rich dataset needed for proof-of-concept validation and Phase III planning.
Phase III represents the most data-intensive stage of drug development, often spanning hundreds of sites across dozens of countries. QuantClinica EDC handles the scale with configurable data validation pipelines, centralised monitoring dashboards, and cross-study consistency checks. Multi-language CRFs, region-specific randomisation schemes, and complex visit schedules are managed through a single protocol configuration, while real-time data review tools enable clinical teams to monitor patient safety and data quality at scale.
After regulatory approval, Phase IV studies continue to monitor long-term safety, real-world effectiveness, and rare adverse events. QuantClinica's Phase IV module supports pragmatic trial designs, registry-based data collection, and integration with electronic health records for minimal-burden data capture. Long-term follow-up workflows, pregnancy registry tracking, and signal detection algorithms help sponsors fulfil post-marketing commitments efficiently.
Yes. QuantClinica EDC is fully 21 CFR Part 11 compliant, providing electronic signatures, system access controls, audit trails, and validation documentation. Our platform has been used in multiple FDA-regulated submissions and passes regulatory audit scrutiny.
Data security is architected at every layer — encryption at rest (AES-256) and in transit (TLS 1.3), role-based access controls with granular permission sets, network isolation, and tenant-level data separation. All access is logged in tamper-evident audit trails. We also support data residency requirements for jurisdictions that mandate local data storage.
Absolutely. The platform supports unlimited languages for CRFs, patient-facing materials, and investigator dashboards. Site-level configuration allows each country to operate under its own regulatory framework while study-level oversight provides sponsors with consolidated visibility across all regions.
QuantClinica provides RESTful APIs, OData endpoints, FHIR R4 connectivity, and flat-file exchange formats (CSV, XML, JSON) for integration with clinical trial management systems, laboratory information management systems, electronic health records, safety databases, and analytics platforms. Our professional services team can manage end-to-end integration for enterprise deployments.
See how QuantClinica EDC can support your next clinical trial.
Request a Demo